Our in vivo results confirmed that IL-6 and CXCL11 are significantly downregulated in RA patients treated with tofacitinib, while IL-8, IL-17, IFN-γ, CCL2, CXCL9, and CXCL10 were not affected. Here, CXCL10 is linked to rheumatoid arthritis.